Evaluation of HPV Vaccine Immunity in High-risk Women: a Pilot Study
Latest Information Update: 07 Feb 2024
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Pharmacodynamics
- 30 Jan 2024 Status changed from active, no longer recruiting to completed.
- 20 Sep 2022 Planned primary completion date changed from 1 Jun 2023 to 1 Apr 2023.
- 20 Sep 2022 Status changed from not yet recruiting to active, no longer recruiting.